Rule 3.19A.2

# **Appendix 3Y**

## **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Paradigm Biopharmaceuticals Limited
ABN	94 169 346 963

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Christopher Maxwell Fullerton
Date of last notice	08 March 2019

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and indirect interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Christopher Maxwell Fullerton  Mandalay Capital Pty Ltd ATF Mandalay Investment Trust - Christopher Fullerton is a Beneficiary
	Mandalay Capital Pty Ltd ATF Caledonia Investment Trust – Christopher Fullerton is a Beneficiary
	Christalgia Pty Ltd - Christopher Fullerton is a Director
Date of change	23 April 2019

<sup>+</sup> See chapter 19 for defined terms.

No. of securities held prior to change	Christopher Maxwell Fullerton - 36,000 Fully Paid Ordinary Shares  Mandalay Capital Pty Ltd ATF Mandalay Investment Trust - 600,000 Fully Paid Ordinary Shares registered in the name of Mandalay Capital Pty Ltd. Mr Christopher Fullerton is a beneficiary  Mandalay Capital Pty Ltd ATF Caledonia Investment Trust - 200,000 Fully Paid Ordinary Shares registered in the name of Mandalay Capital Pty Ltd. Mr Christopher Fullerton is a Beneficiary.  Total No. of shares held after change - 836,000 Fully Paid Ordinary Shares
Class	Ordinary Shares
Number acquired	19,500
Number disposed	Not applicable
Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation	\$32,130

Appendix 3Y Page 2 01/01/2011

<sup>+</sup> See chapter 19 for defined terms.

No. of securities held after change	Christopher Maxwell Fullerton
	- 40,500 Fully Paid Ordinary Shares
	Mandalay Capital Pty Ltd ATF Mandalay Investment Trust  - 600,000 Fully Paid Ordinary Shares registered in the name of Mandalay Capital Pty Ltd. Mr Christopher Fullerton is a beneficiary
	Mandalay Capital Pty Ltd ATF Caledonia Investment Trust  - 200,000 Fully Paid Ordinary Shares registered in the name of Mandalay Capital Pty Ltd. Mr Christopher Fullerton is a Beneficiary.
	Christalgia Pty Ltd  - 15,000 Fully Paid Ordinary Shares registered in the name of Christalgia Pty Ltd. Mr Christopher Fullerton is a Director.
	Total No. of shares held after change - 855,500 Fully Paid Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market trade

### Part 2 - Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest	Not applicable
Name of registered holder (if issued securities)	Not applicable
Date of change	Not applicable

<sup>+</sup> See chapter 19 for defined terms.

No. and class of securities to which interest related prior to change  Note: Details are only required for a contract in relation to which the interest has changed	Not applicable
Interest acquired	Not applicable
Interest disposed	Not applicable
Value/Consideration  Note: If consideration is non-cash, provide details and an estimated valuation	Not applicable
Interest after change	Not applicable

## Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a *closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

Appendix 3Y Page 4 01/01/2011

<sup>+</sup> See chapter 19 for defined terms.